

ORAL PRESENTATION

Open Access

Development, reliability and validity of the Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS)

Joshua Burns^{1*}, Richard Finkel², Tim Estilow², Andy Hiscock³, Matilde Laura⁴, Polly Swingle⁵, Agnes Patzko⁵, Allan Glanzman², Gyula Acsadi⁶, Francesco Muntoni³, Mary Reilly⁴, Davide Pareyson⁷, Isabella Moroni⁷, Emanuela Pagliano⁷, Sindhu Ramchandren⁵, Kate Eichinger⁸, Monique Ryan⁹, Robert Ouvrier¹, Michael Shy⁵, Rosemary Shy⁶

From Australasian Podiatry Council Conference 2011 Melbourne, Australia. 26-29 April 2011

Background

Charcot-Marie-Tooth disease (CMT) causes peripheral nerve demyelination, progressive foot weakness, cavus deformity, difficulty walking and sensory loss. There is a need for accurate, sensitive and disease-relevant measures of young children through to adolescents with CMT to enable accurate assessment of baseline performance, monitor disease severity longitudinally, and determine responses to existing and novel foot and ankle interventions. Our objective was to develop a multidimensional scale to measure disease severity of children with CMT, known as the CMT Pediatric Scale (CMTPedS).

Methods

The CMTPedS has undergone a thorough development process: (1) definition of the construct; (2) generation of the item pool; (3) choice of scoring format; (4) peerreview (face validity); (5) pilot testing; (6) standardised training; (7) inter-rater reliability of four international centres assessing eight children with CMT; (8) multicenter implementation.

Results

Findings of the development process: (1) the CMTPedS is a composite scale with broad application to measure disease severity of childhood CMT with eight domains capturing symptoms, foot/ankle involvement, lower limb

sensation, hand dexterity/strength, balance, motor function; (2) a large pool of items generated from the literature were reduced based on disease-specificity, functional/patient-relevance, reliability/validity, published norms, test duration and ease of interpretation; (3) items collapsed to 5-point Likert scales using z-scores based on age/gender norms; (4) quality, appropriateness and suitability of items peer-reviewed by 23 expert clinicians/researchers/patient representatives at the 168th European Neuromuscular Centre International Workshop; (5) pilot-tested on four children with CMT to check for administration problems, item instructions, order and duration; (6) clinicians from USA, UK, Italy and Australia trained through workshops, online manual and video resources; (7) all items exhibited good to excellent inter-rater reliability (ICC_{2.4}0.78-0.99) (8) a multicenter natural history study of children with all types of CMT aged 3-17 years is underway, with 90 children recruited to date.

Conclusions

Application and psychometric validation of the CMTPedS continues. We plan to apply the final CMTPedS as the primary outcome in clinical trials of podiatric, pharmacological and surgical interventions.

Author details

¹Children's Hospital at Westmead, Sydney, Australia. ²Children's Hospital of Philadelphia, PA, USA. ³Great Ormond Street Hospital, London, UK. ⁴National Hospital for Neurology and Neurosurgery, London, UK. ⁵Wayne State University Detroit, MI, USA. ⁶Children's Hospital of Michigan, Detroit, MI, USA.

^{*} Correspondence: Joshuab2@chw.edu.au ¹Children's Hospital at Westmead, Sydney, Australia Full list of author information is available at the end of the article



⁷C. Besta Neurological Institute, Milan, Italy. ⁸University of Rochester, Rochester, NY, USA. ⁹Royal Children's Hospital, Melbourne, Australia.

Published: 20 May 2011

doi:10.1186/1757-1146-4-S1-O12

Cite this article as: Burns et al.: Development, reliability and validity of the Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS). Journal of Foot and Ankle Research 2011 4(Suppl 1):012.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

